StockNews.com initiated coverage on shares of GlycoMimetics (NASDAQ:GLYC – Get Rating) in a research report issued on Friday. The brokerage set a “hold” rating on the biotechnology company’s stock. Separately, Zacks Investment Research upgraded GlycoMimetics from a “hold” rating to a “buy” rating and set a $0.75 price target on the stock in a research […]
GlycoMimetics (NASDAQ:GLYC – Get Rating) and Nature’s Sunshine Products (NASDAQ:NATR – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability. Analyst Ratings This is a breakdown of recent ratings […]
StockNews.com assumed coverage on shares of GlycoMimetics (NASDAQ:GLYC – Get Rating) in a report issued on Thursday. The firm set a “hold” rating on the biotechnology company’s stock. Shares of NASDAQ:GLYC opened at $1.07 on Thursday. The company has a market capitalization of $55.98 million, a P/E ratio of -0.87 and a beta of 1.82. […]